Richard Hobbs - Revision history

Claire Robinson at 09:18, 4 September 2009

2009-09-04T09:18:50Z

Marisa de Andrade at 21:16, 3 September 2009

2009-09-03T21:16:38Z

Marisa de Andrade: New page: {{Template:Pharma_Portal_badge}} Richard Hobbs has been a Professor and Head of Primary Care and General Practice at the School of Medicine, University of Birmingham since 1991. Prior to ...

2009-09-03T21:15:23Z

New page: {{Template:Pharma_Portal_badge}} Richard Hobbs has been a Professor and Head of Primary Care and General Practice at the School of Medicine, University of Birmingham since 1991. Prior to ...

New page

{{Template:Pharma_Portal_badge}}

Richard Hobbs has been a Professor and Head of Primary Care and General Practice at the School of Medicine, University of Birmingham since 1991. Prior to that, he served as Associate Dean for Finance and Strategic Planning and for External Affairs. He sits on several scientific and research funding boards, including currently the [[European Society of Cardiology]] (ESC) [[Diagnosis of Heart Failure Research Group]]; the Advisory Council to the [[Medical Research Council]]; the Secondary Prevention Panel for the [[British Heart Foundation]] and the NHS R&D HTA Commissioning Board.

As a consultant, he has worked on NHS policy including advisory roles for National Service Frameworks for CHD and for Heart Failure and for several [[NICE]] assessments. His medical society work has included [[Council of the British Cardiac Society]], Chairmanship of both the [[European Primary Care Cardiovascular Society]] and the [[British Primary Care Cardiovascular Society]]; and founding board member of the [[British Society of Heart Failure]]. <ref>[http://www.pcpoh.bham.ac.uk/primarycare/about/staff_members/hobbsr.shtml University of Birmingham School of Health and Population Sciences]. Accessed 4 September 2009.</ref>

In 2005, he was chairman for the [[Primary Care Cardiovascular Society]] ([[PCCS]]) and thanked the pharmaceutical industry for its continued support in his annual report. In the same year, the PCCS established a second Special Interest Group to represent GPs with special interests in cardiology and clinical practitioners which was supported by the [[British Journal of Cardiology]], [[AstraZeneca]] and [[Servier]]. [[AstraZeneca]], [[Bristol-Myers Squibb]], Kellogs, [[Medtronic]], [[Merck Sharp & Dohme]]/[[Schering Plough]], [[Merck Pharmaceuticals Omron]], [[Pfizer]], [[Provexis]], [[Sanofi-Aventis]] provided sponsorship for the PCCS Annual Scientific Meeting in the same year.<ref>BCS. [http://www.bcs.com/pages/news_full.asp?NewsID=2509 Affiliate update December 2005 - Primary Care Cardiovascular Society]. Accessed 4 September 2009.</ref>

In 2006, he chaired the steering committee for JEWEL I - a [[Pfizer]]-funded program showing that single-pill amlodipine/atorvastatin therapy (Caduet) is an effective treatment simultaneously reducing both hypertension and cholesterol levels.<ref>Red Orbit.[http://www.redorbit.com/news/health/538638/pfizers_caduet_improves_cardio_risk_factors_treatment/index.html Pfizer's Caduet Improves Cardio Risk Factors Treatment]. Accessed 4 September 2009.</ref>

==Notes==

<references/>
[[Category:Pharma]]
[[Category:Pharmaceutical Industry]]

@@ Line 1: / Line 1: @@
 {{Template:Pharma_Portal_badge}}
-Richard Hobbs has been a Professor and Head of Primary Care and General Practice at the School of Medicine, University of Birmingham since 1991. Prior to that, he served as Associate Dean for Finance and Strategic Planning and for External Affairs. He sits on several scientific and research funding boards, including currently the [[European Society of Cardiology]] (ESC) [[Diagnosis of Heart Failure Research Group]]; the Advisory Council to the [[Medical Research Council]]; the Secondary Prevention Panel for the [[British Heart Foundation]] and the NHS R&D HTA Commissioning Board.
+[[Richard Hobbs]] has been a Professor and Head of Primary Care and General Practice at the School of Medicine, University of Birmingham since 1991. Prior to that, he served as Associate Dean for Finance and Strategic Planning and for External Affairs. He sits on several scientific and research funding boards, including currently the [[European Society of Cardiology]] (ESC) [[Diagnosis of Heart Failure Research Group]]; the Advisory Council to the [[Medical Research Council]]; the Secondary Prevention Panel for the [[British Heart Foundation]] and the NHS R&D HTA Commissioning Board.
 As a consultant, he has worked on NHS policy including advisory roles for National Service Frameworks for CHD and for Heart Failure and for several [[NICE]] assessments. His medical society work has included [[Council of the British Cardiac Society]], Chairmanship of both the [[European Primary Care Cardiovascular Society]] and the [[British Primary Care Cardiovascular Society]]; and founding board member of the [[British Society of Heart Failure]]. <ref>HaPS.[http://www.pcpoh.bham.ac.uk/primarycare/about/staff_members/hobbsr.shtml University of Birmingham School of Health and Population Sciences]. Accessed 4 September 2009.</ref>
@@ Line 7: / Line 7: @@
 In 2005, he was chairman for the [[Primary Care Cardiovascular Society]] ([[PCCS]]) and thanked the pharmaceutical industry for its continued support in his annual report. In the same year, the PCCS established a second Special Interest Group to represent GPs with special interests in cardiology and clinical practitioners which was supported by the [[British Journal of Cardiology]], [[AstraZeneca]] and [[Servier]]. [[AstraZeneca]], [[Bristol-Myers Squibb]], Kellogs, [[Medtronic]], [[Merck Sharp & Dohme]]/[[Schering Plough]], [[Merck Pharmaceuticals Omron]], [[Pfizer]], [[Provexis]], [[Sanofi-Aventis]] provided sponsorship for the PCCS Annual Scientific Meeting in the same year.<ref>BCS. [http://www.bcs.com/pages/news_full.asp?NewsID=2509 Affiliate update December 2005 - Primary Care Cardiovascular Society]. Accessed 4 September 2009.</ref>
-In 2006, he chaired the steering committee for JEWEL I - a [[Pfizer]]-funded program showing that single-pill amlodipine/atorvastatin therapy (Caduet) is an effective treatment simultaneously reducing both hypertension and cholesterol levels.<ref>Red Orbit.[http://www.redorbit.com/news/health/538638/pfizers_caduet_improves_cardio_risk_factors_treatment/index.html Pfizer's Caduet Improves Cardio Risk Factors Treatment]. Accessed 4 September 2009.</ref>
+In 2006, he chaired the steering committee for JEWEL I - a [[Pfizer]]-funded program showing that single-pill amlodipine/atorvastatin therapy (Caduet) is an effective treatment for hypertensive patients with additional cardiovascular risk factors, simultaneously reducing both hypertension and cholesterol levels.<ref>Red Orbit.[http://www.redorbit.com/news/health/538638/pfizers_caduet_improves_cardio_risk_factors_treatment/index.html Pfizer's Caduet Improves Cardio Risk Factors Treatment]. Accessed 4 September 2009.</ref>
 ==Notes==